Eagle Pharmaceuticals Interest Expense 2011-2026 | EGRX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Eagle Pharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
4.04 M	1.64 M	2.58 M	2.69 M	2.74 M	1.14 M	8 K	11 K	8 K	309 K	91 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.04 M	8 K	1.39 M

Quarterly Interest Expense Eagle Pharmaceuticals

2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.45 M	1.52 M	-	1.15 M	552 K	366 K	-	396 K	422 K	422 K	-	489 K	786 K	889 K	-	628 K	665 K	686 K	-	743 K	701 K	675 K	-	527 K	40 K	27 K	-	3 K	3 K	-	-	5 K	3 K	1 K	1 K	2 K	5 K	1 K	-	309 K	16 K	145 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.52 M	1 K	426 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	501 K	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
AcelRx Pharmaceuticals ACRX	134 K	-	7.5 %	$ 6.35 M	USA
DURECT Corporation DRRX	2.4 M	-	-	$ 50.1 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Cumberland Pharmaceuticals CPIX	496 K	$ 5.8	-1.19 %	$ 86.2 M	USA
Cronos Group CRON	-241 K	$ 2.74	-0.18 %	$ 1.05 B	Canada
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Harrow Health HROW	47 K	$ 33.8	2.42 %	$ 1.24 B	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Bausch Health Companies BHC	-142 M	$ 5.38	-1.74 %	$ 2 B	Canada
Organogenesis Holdings ORGO	-5 K	$ 2.63	-1.13 %	$ 333 M	USA
Pacira BioSciences PCRX	-373 K	$ 24.62	5.44 %	$ 1.14 B	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.05	0.48 %	$ 113 M	Canada
Solid Biosciences SLDB	824 K	$ 6.86	3.63 %	$ 600 M	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 1.07	-2.73 %	$ 1.33 M	USA
Jupiter Wellness JUPW	152 K	-	-	$ 33.6 M	USA
Tilray TLRY	46.6 M	$ 5.44	2.83 %	$ 3.36 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Evolus EOLS	-539 K	$ 6.19	1.56 %	$ 399 M	USA
Sundial Growers SNDL	81 K	$ 1.45	-0.34 %	$ 3.37 M	Canada
Emergent BioSolutions EBS	54.2 M	$ 9.26	9.59 %	$ 495 M	USA
Veru VERU	768 K	$ 2.29	-2.47 %	$ 33.5 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Assertio Holdings ASRT	2.78 M	$ 23.45	0.02 %	$ 150 M	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
cbdMD YCBD	34.3 K	$ 0.75	-1.51 %	$ 3.02 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 7.11	0.99 %	$ 281 M	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	3.13 M	$ 0.7	-4.47 %	$ 35 M	USA
Viatris VTRS	471 M	$ 16.36	-1.74 %	$ 19.1 B	USA
Zomedica Corp. ZOM	-144 K	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	27 K	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	-623 K	$ 0.76	-4.48 %	$ 27.3 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	27.3 K	$ 0.78	2.67 %	$ 3.35 M	China
TherapeuticsMD TXMD	300 K	$ 2.12	-	$ 24.5 M	USA